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A nomogram to determine required seed air kerma 
strength in planar 131Cesium permanent seed 
implant brachytherapy
Emily Hubley, MSc1, Michael Trager, MS1, Voichita Bar-Ad, MD1, Adam Luginbuhl, MD2, Laura Doyle, PhD1 
1Department of Radiation Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, USA, 2Department of Otolaryngology Head 
and Neck Surgery, Thomas Jefferson University Hospital, Philadlephia, PA, USA 
Abstract 
Purpose: Intraoperatively implanted Cesium-131 (131Cs) permanent seed brachytherapy is used to deliver highly 
localized re-irradiation in recurrent head and neck cancers. A single planar implant of uniform air kerma strength 
(AKS) seeds and 10 mm seed-to-seed spacing is used to deliver the prescribed dose to a point 5 mm or 10 mm perpen-
dicular to the center of the implant plane. Nomogram tables to quickly determine the required AKS for rectangular 
and irregularly shaped implants were created and dosimetrically verified. By eliminating the need for a full treatment 
planning system plan, nomogram tables allow for fast dose calculation for intraoperative re-planning and for a second 
check method. 
Material and methods: TG-43U1 recommended parameters were used to create a point-source model in MATLAB. 
The dose delivered to the prescription point from a single 1 U seed at each possible location in the implant plane was 
calculated. Implant tables were verified using an independent seed model in MIM Symphony LDR™. Implant tables 
were used to retrospectively determine seed AKS for previous cases: three rectangular and three irregular. 
Results: For rectangular implants, the percent difference between required seed AKS calculated using 
MATLAB and MIM was at most 0.6%. For irregular implants, the percent difference between MATLAB and MIM cal-
culations for individual seed locations was within 1.5% with outliers of less than 3.1% at two distal locations (10.6 cm 
and 8.8 cm), which have minimal dose contribution to the prescription point. The retrospectively determined AKS for 
patient implants using nomogram tables agreed with previous calculations within 5% for all six cases. 
Conclusions: Nomogram tables were created to determine required AKS per seed for planar uniform AKS 131Cs 
implants. Comparison with the treatment planning system confirms dosimetric accuracy that is acceptable for use as 
a second check or for dose calculation in cases of intraoperative re-planning. 
J Contemp Brachytherapy 2019; 11, 1: 91–98 
DOI: https://doi.org/10.5114/jcb.2019.82716
Key words: brachytherapy, Cesium-131, intraoperative brachytherapy, permanent seed implant, head and neck 
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Purpose
The standard of care for patients with recurrent head 
and neck cancers is surgical salvage when feasible. The 
role and use of radiation are less well-defined; many pa-
tients in this group have previously received radiation 
and/or chemotherapy, which often limits the use of addi-
tional radiation due to the high-risk of toxicities. 
Unlike external beam radiation therapy, Cesium-131 
(131Cs) permanent brachytherapy seed implants can be 
used to deliver highly localized re-irradiation in this set-
ting. Cesium-131 is an electron-capture radionuclide that 
is gaining popularity in permanent seed implant (PSI) 
brachytherapy. The average photon energy of IsoRay™’s 
Proxcelan 131Cs is 30.4 keV [1], which is slightly higher 
than that of Iodine-125 (125I) or Palladium-103 (103Pd) 
and can lead to improved dose homogeneity in prostate 
PSI [2]. Furthermore, the half-life of 131Cs is 9.7 days [1], 
shorter than that of 125I or 103Pd, which can reduce the 
overall exposure to family members, and can be advanta-
geous from a radiobiological standpoint [3]. 
Since Food and Drug Administration (FDA) 510(k) 
approval in 2003, the use of 131Cs for PSI has been in-
vestigated for the treatment of prostate cancer [2,4,5,6], 
brain metastasis [7], recurrent gynecological cancers 
[8,9], lung cancer [10], and recurrent head and neck 
cancers [11,12,13]. Dosimetric parameters such as en-
ergy spectrum and dose-rate constant have been deter-
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mined using Monte Carlo simulations, radiochromic 
film, and thermoluminescent dosimetry measurements 
[1,14,15,16,17,18,19]. 
At our institution, 131Cs implants following historical 
planar implant techniques are performed for resectable 
recurrent head and neck cancers at the time of surgical 
intervention. Treatment planning is typically done prior 
to surgery with a sophisticated brachytherapy treatment 
planning system (TPS), however, sometimes the treat-
ment plan is changed during surgery due to intraoper-
ative findings. In these cases, a nomogram can be used 
by the physicist to provide an estimate of the adjusted 
implant dose. Additionally, a nomogram can be used as 
a secondary check of the treatment plan created with the 
brachytherapy dose calculation system for all cases. Un-
like other radionuclides, 131Cs was first used in PSI well 
after sophisticated TPS were standard in clinics, so stan-
dard implant tables have not been published [20,21,22]. 
In this work, nomograms for efficient and simple 
point dose calculation of rectangular and irregular planar 
implants prescribed to a point 5 mm or 10 mm away from 
an implant plane are presented. The prescription dose is 
not defined, and nomogram tables may be used for any 
prescribed dose. 
Material and methods 
Clinical treatment planning and prescription 
Cesium-131, Proxcelan Model CS-1 Rev2 (Isoray 
Medical, Richmond, WA) (Figure 1) implants are used to 
provide highly localized re-irradiation in recurrent head 
and neck patients at the time of salvage surgery. Source 
placement follows historical planar implant techniques. 
Uniform strength seeds for PSI are ordered pre-loaded 
in individual strands or in a mesh. Seeds are stranded 
10 mm apart, with the intent to implant individual 
strands 10 mm apart. If a mesh is ordered, seeds are sewn 
into the mesh in a 10 mm by 10 mm grid pattern. The 
number of seeds required for an implant is determined 
by the estimated size of the future post-resection cavity. 
Dose is prescribed to a point 5 mm from the center of 
a single-plane implant. If the prescription point falls di-
rectly above a seed, as is the case for an implant with an 
odd number of rows and/or columns, the prescription 
point is moved 5 mm parallel to the implant plane in 
one or two directions such that it lies in between four 
seeds. For rectangular or symmetric irregular implants, 
the direction of the shift is irrelevant; for asymmetric 
implants, the prescription point is shifted towards the 
side(s) with more seeds (Figure 2). Air kerma strength 
per seed in U is selected such that the prescribed dose is 
delivered to this point and is rounded to 1 decimal place 
for seed ordering. This rounding error will be ≤ 3% for 
all seed activities ≥ 1.5 U. 
While there is a number of commercially available 
brachytherapy treatment planning systems, most of 
them do not cater to the specifics of this type of free hand 
strand or mesh placement within the surgical cavity. Cur-
rently, treatment planning is performed in MIM Sympho-
ny LDR™ (version 6.5, Cleveland, Ohio). The estimated 
resection cavity dimensions and optimal implant plane 
are determined in collaboration with the radiation oncol-
ogist and surgeon. Seeds are manually placed in a grid 
pattern, and the prescription point is identified and de-
lineated. The seed AKS is iteratively adjusted such that 
the prescription dose is delivered to the prescribed depth. 
This planning process requires coordination between the 
medical physicist, radiation oncologist, and surgeon, 
and can take a few hours from scan import, physician(s) 
contouring, and physicist planning to final physician(s) 
approval. Treatment planning using a nomogram can be 
done in minutes based on physician described implant 
dimensions rather than import and contouring of 3D vol-
ume imaging. 
Rectangular implant tables 
Calculations for rectangular implant tables were 
performed using MATLAB (Mathworks®, Natick, MA). 
The 131Cs (Rev 2) point source and line source seed 
model data, as per the American Association of Phys-
icists in Medicine’s TG-43 equation [23] (dose-rate 
constant, radial dose function, and 1D/2D anisotropy 
functions [17]) were input into MATLAB. Linear inter-
polation between each data point was used. The dose-
rate at a prescription point 5 mm or 10 mm away from 
the implant plane was calculated for rectangular arrays 
of 1 U seeds placed 10 mm apart in a grid pattern rang-
ing from 1 × 1 up to 16 × 16 seeds. The total dose de-
livered by a single seed n was calculated by integrating 
the dose-rate of that seed D
.
0,n  over the duration of the 
permanent implant. 
Dn = D
.
0,n
∞
∫
0
dt1
(t/T1/2)
2
The total dose delivered to the prescription point over 
the lifetime of the implant was calculated by summing the 
contribution from each seed n in an implant of N seeds: 
Dtotal = D
.
0,n D
.
0,n
∞
∫
0
N
∑
n = 1
N
∑
n = 1
dt = 1
(t/T1/2)
2
T1/2
ln2Fig. 1. The source geometry for Proxcelan 131Cs seeds.  
Image provided by IsoRay Medical 
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Irregular implants 
To determine the dose delivered by a non-rectangu-
lar planar implant, the dose rate at the 5 mm and 10 mm 
prescription points from a single 1 U seed at each pos-
sible location in the 16 × 16 cm2 grid was calculated in 
MATLAB using the methods described above for regular 
implants. This was done using the 1D and 2D formalisms. 
Verification of implant tables using MIM 
Symphony LDR 
Verification of the implant tables was performed in 
MIM Symphony LDR™ for the 1D and 2D formalisms. 
The point source seed model data were input into MIM 
during previous commissioning [24]. Seeds were placed 
at a distance of 10 mm center-to-center in a single planar 
arrangement. The total dose delivered by a 1 U seed was 
recorded for each possible seed position in the 16 × 16 cm2 
grid to verify the irregular implant tables, and the total 
dose from an array of seeds was recorded to verify the 
rectangular implant tables. These values were compared 
to those calculated in MATLAB. 
Application to patient implants 
Nomogram tables were used retrospectively to de-
termine the required seed AKS for the three most re-
cent rectangular and three most recent irregular clin-
ical implant cases. All six implants were prescribed 
60 Gy to a point 5 mm from the implant plane. The im-
plant geometry and prescription point for each patient 
are shown in Figure 2. 
For the rectangular plans, the dose rate in the im-
plant table represents a rectangular arrangement of 1 U 
seeds. The desired AKS is calculated using the following 
equation: 
Required AKS = 
Prescription dose
Dose delivered to prescription point 
by 1 U seeds
For irregular seed arrangements, the desired AKS per 
seed is obtained by dividing the prescription dose by the 
sum of the total dose delivered to the prescription point 
by each seed in the implant: 
Required AKS = 
Prescription dose
∑n seeds Dose delivered to prescrip-
tion point by seed n
The required AKS calculated by the implant tables 
and by MIM were recorded. 
Results 
Rectangular implant tables 
The total dose delivered to 5 mm and 10 mm prescrip-
tion points by a planar array of 1 U seeds calculated in 
MATLAB are presented in Table 1 (1D formalism) and 
Table 2 (2D formalism). Using the 1D formalism, all dif-
ferences in required AKS between MATLAB and MIM 
were less than 0.6%. Using the 2D formalism, all differ-
ences were less than 1.4%. 
Irregular tables 
The dose delivered over the lifetime of an implant 
by a 1 U seed at each location in an implant to prescrip-
tion points located 5 mm and 10 mm perpendicular to 
the center of the implant plane are presented in Table 3 
using the 1D and 2D formalisms. The numbering along 
the table edges are used to represent the seed indexing 
number, and not a distance from the prescription point. 
To highlight differences between the two dose calculation 
formalisms, bolded values indicate a difference between 
line and point source models that are greater than 5% 
for a single seed’s contribution to the prescription point; 
bolded and underlined values indicate greater than 10%, 
with a maximum of 16.9%. 
Application to patient plans 
The required AKS per seed was determined clini-
cally using MIM and then retrospectively using the im-
plant tables for the three most recent rectangular and 
three most recent irregular implants. The seed AKS cal-
culated using MIM and implant tables are presented in 
Table 4. For all six patient plans, the percent difference 
was less than 3%. 
Discussion 
The nomogram tables created with MATLAB show 
good agreement with those calculated using MIM (maxi-
mum difference of 3.0%). For seeds very close to the pre-
Fig. 2. The implant geometry for the three most recent 
rectangular and irregular patients. The projection of the 
prescription point onto the implant plane is indicated by 
the blue ‘x’. The prescription point is 5 mm perpendicular 
to the implant plane for all six implants
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scription point, differences between MIM and MATLAB 
are attributed to the large effect of the inverse square law 
for small uncertainties in manual seed and prescription 
point placement in MIM as well as a large volume averag-
ing effect. For seeds located further from the prescription 
point, differences are attributed to limited significant fig-
ures in the dose value displayed in MIM, which has a larg-
er relative effect when the dose at the prescription point 
is very small. The AKS determined with the tables agreed 
with MIM-determined AKS for six previous implants 
within 3%. Differences are due to errors in manual seed 
and prescription point placement in MIM and rounding 
of AKS to a single decimal place for ordering. While mea-
surement tools are available in MIM, precise placement of 
a prescription point and measurement perpendicular to 
implant plane are challenging especially when the implant 
plane is not aligned with an axial, coronal, or sagittal slice 
of the image set. MIM Symphony LDR™ allows the user to 
overlay the digital projection of an external prostate seed 
implant template but the templates are limited in size and 
often not large enough. Due to these limitations, the nomo-
gram tables provide more consistent dose calculations than 
manually creating implants in MIM Symphony LDR™. 
Although treatment planning and seed ordering are 
performed during a preoperative CT planning session us-
ing sophisticated treatment planning software, the final 
dose is modified intraoperatively to fit the surgical de-
fect in 10-20% of cases. Intraoperative considerations that 
can lead to these alterations include: location and expo-
sure of the carotid artery within the operative field, bony 
anatomy that causes contour alterations, free flap recon-
struction, and unexpected changes in the area of greatest 
concern for recurrence. Nomogram tables are used in the 
operating room to provide the surgeon and radiation on-
cologist an accurate dose estimate based on a number or 
arrangement of seeds that differs from the preoperative 
planning session. A second check of the pre-planning 
dose is performed for all cases. 
Unlike other permanent seed implant radionuclides, 
131Cs was not used clinically until brachytherapy TPS 
were common in radiation therapy departments. Be-
cause of this, historical implant systems and data tables 
do not exist. The uniform seed strength and uniform 
seed spacing reported here is reminiscent of the Quimby 
system [25]. However, the choice of a prescription point 
that is not directly above a seed means that the prescrip-
tion dose is the minimum dose in the central region of 
the 5 mm or 10 mm prescription point plane. The Man-
chester [26] and Quimby systems are prescribed such 
that the prescription dose is the modal or maximum 
dose in the treatment plane, respectively. The system of 
implant dosimetry reported here would therefore deliv-
er more dose than an implant prescribed using the Man-
chester or Quimby conventions. 
Conclusions 
Nomogram tables to determine AKS per seed for rect-
angular and irregular planar 131Cs implants prescribed to 
5 mm and 10 mm from the implant plane are presented. 
The nomogram tables may be adapted to any prescrip-
tion dose. Tables were verified against MIM Symphony 
LDR™ planning system, including previous patient plans 
and yield seed activities well within clinically acceptable 
accuracy. These nomogram tables reduce time required 
for treatment planning or independent verification of 
a treatment plan. They also facilitate treatment planning 
in the operating room when patient anatomy requires an 
implant to deviate from the treatment plan. 
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